



# WILLIAM COOLEY REGULATORY & SCIENTIFIC AFFAIRS CAREER ACHIEVEMENT AWARD

## PAST WINNERS



### **Douglas Bierer, Ph.D. (2024)**

Dr. Doug Bierer has made exceptional strides that led to increased access of consumer healthcare products during his distinguished career at Procter & Gamble (P&G). Notably, his leadership in the Rx-to-OTC switch of omeprazole revolutionized the landscape of self-care. Since retiring from P&G, Bierer continued to shape the regulatory environment through his role as VP of Regulatory & Scientific Affairs at CHPA and as a consultant for industry issues related to toxicology, regulatory affairs, and clinical development.

### **Edwin Hemwall, Ph.D. (2023)**

“Ed has had an exceptional career that has truly improved public health through innovation in regulatory science. It’s really thrilling to highlight a role model like Ed, who is an inspiration to this generation of regulatory leaders and future generations.”

- Lisa Parks, Former CHPA SVP of Regulatory & Scientific Affairs

### **Barbara Kochanowski, Ph.D. (2023)**

“As someone who has the pleasure of working with Barb on a daily basis, I am in constant awe of her intelligence, her organization, her calmness, her humanity, and her commitment to this industry. She has been at the forefront of every major regulatory issue for the last few decades, and her imprint on CHPA and our entire industry will most certainly endure.”

- Scott Melville, CHPA President and CEO

### **William E. Cooley, Ph.D. (2022)**

Dr. Cooley’s career in the self-care industry spans more than 40 years, first at Procter & Gamble Co. and then as an independent consultant. During this time, Dr. Cooley has made significant impacts on our industry through his leadership of several oral care teams, which helped build the oral care regulatory framework and, more broadly, the OTC Monograph system we have today.

### **Sue James (2022)**

With a career consisting of 40 years in the self-care industry, 23 of which were spent leading global regulatory affairs at GSK, now Haleon, Ms. James’s expertise in OTC regulatory issues, especially Rx-to-OTC switch, has resulted in increased consumer access to many first-in-class products. In some cases, use of ancillary educational materials helped set a precedent for Nonprescription Drug Safe Use Regulatory Expansion (NSURE), now known as Additional Condition for Nonprescription Use (ACNU).

The Consumer Healthcare Products Association (CHPA) invites you to submit nominations for the 2024 Regulatory & Scientific Affairs Career Achievement Award to be presented on September 9, 2025, at the annual Regulatory, Scientific & Quality Conference (RSQ). The William Cooley Career Achievement Award recipient will be selected by the CHPA RSAC Policy & Planning Subcommittee from nominations submitted online by July 24, 2025.

» **2025 Nominations**